By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > Jazz Pharmaceuticals Files Complaint Against FDA for Decision on Avadel Pharmaceuticals’ Lumryz
Investing

Jazz Pharmaceuticals Files Complaint Against FDA for Decision on Avadel Pharmaceuticals’ Lumryz

News Room
Last updated: 2023/06/23 at 6:34 PM
By News Room
Share
1 Min Read
SHARE

By Denny Jacob

Jazz Pharmaceuticals on Thursday said its subsidiary filed a complaint alleging that the Food and Drug Administration unlawfully approved Avadel Pharmaceuticals’ new drug application for Lumryz.

The biopharmaceutical company said in a regulatory filing, which outlined their complaint, that the FDA acted outside of its authority under the Orphan Drug Act. Jazz Pharmaceuticals said its product Xywav had orphan drug exclusivity. It said that the FDA approved Lumryz’s new drug application and granted it orphan drug exclusivity based on its own findings that it boosts patient care, and is therefore clinically superior to Xywav and another drug it produces, Xyrem. Both drugs treat cataplexy, or excessive daytime sleepiness, in adults with narcolepsy.

Jazz Pharmaceuticals described Lumryz as an extended-release reformulation of Xyrem.

The Ireland-based company said among the complaint’s allegations are that the FDA acted without lawful basis when it determined that the dosing regimen for Lumryz makes a major contribution to patient care.

The complaint was filed in the United States District Court for the District of Columbia.


Write to Denny Jacob at denny.jacob@wsj.com


Read the full article here

News Room June 23, 2023 June 23, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Mohamed El-Erian talks US trade policy fallout, market uncertainty, bitcoin surges above $123,000

Watch full video on YouTube

What Trump’s New Tax Law Means For You | The Bottom Line

Watch full video on YouTube

Nordea Bank Abp (NRDBY) Q2 2025 Earnings Call Transcript

Nordea Bank Abp (OTCQX:NRDBY) Q2 2025 Earnings Conference Call July 17, 2025…

Client Challenge

Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to…

US Senate backs $9bn in cuts to public broadcasting and foreign aid

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?